Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2007-05-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glucocorticoid Treatment for Social Phobia
NCT01574014
Generalized Fear Extinction to Untreated Fear Stimuli in Specific Phobias After Exposure
NCT03907345
The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants
NCT03012035
Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder
NCT00131339
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
NCT00515879
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cortisol
20 mg for 3 times
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Psychiatric disorder other than specific phobia
* Topic glucocorticoid therapy (for large skin parts)
* Inhaled glucocorticoids
* Psychotropic medication
* Pregnancy
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Zurich
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique JF de Quervain, MD, Prof.
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Frank Wilhelm, Prof.
Role: PRINCIPAL_INVESTIGATOR
University of Basel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Basel
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5585-90. doi: 10.1073/pnas.0509184103. Epub 2006 Mar 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007DR3069
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.